Executive Team

Home>
About Us>
Executive Team

President and Business Head – India Formulations

Alok Malik

Alok is President and Business Head of India Formulations, at Glenmark, where he drives our India Formulations and Nepal business across multiple therapy areas, including Dermatology, Respiratory, Oncology, Critical care, Cardio-metabolic, Govt. Institutions; Generics and OTC (over-the-counter).

With over thirty years of experience in managing the life cycle of pharmaceutical brands, he has successfully launched over a hundred products across major therapy areas in the Indian pharmaceutical market. He has played a key role in facilitating seamless business transitions, following mergers and brand acquisitions.

Before joining Glenmark in 2018, Alok served as Country Head for Abbott’s diagnostic business in India and spent over a decade combined at Abbott and Piramal Healthcare in various roles. Alok holds a degree in science and an MBA from the University of Indore.

President and Business Head – North America

Marc T. Kikuchi

Marc is President and Business Head of North America at Glenmark, overseeing our operations, strategic initiatives, and growth portfolio in the region.

He has held various roles of increasing responsibility across the pharmaceutical industry. Having over thirty years of experience, he worked with Dr. Reddy’s Laboratories before joining Glenmark in 2024 and has also been associated with Zydus Pharmaceuticals and AmerisourceBergen Corporation, among other organizations.

Marc holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from Carnegie Mellon University.

President and Business Head – Europe and Emerging Markets

Christoph Stoller

Christoph is President and Business Head of Europe and Emerging Markets at Glenmark. He provides strategic leadership to enhance focus and alignment across Europe and emerging markets including Asia, Russia/CIS, the Middle East, Africa and Latin America, aiming to better address patient needs.

With over twenty-five years of experience, Christoph has successfully led and transformed businesses for growth across multiple geographies.

Before joining Glenmark, he was General Manager for Teva´s Germany and Austria cluster and served as Chief Operating Officer – Global Generic Medicines, Europe. He was also President and Board Member of Medicines for Europe, an association representing nearly 70% of the pharmaceutical supply in Europe. His previous roles include significant positions at Zur Rose Group, Helvepharm, DSM, F. Hoffmann-La Roche, and Swiss Re.

Christoph holds a degree in Business Administration from the University of St. Gallen, Switzerland (lic.oec.HSG).

Interim Chief Executive Officer - IGI

Lida Pacaud, M.D.

Lida Pacaud, M.D., is an accomplished physician and expert in oncology drug development. Prior to taking over as a She has served as medical lead for clinical development strategies and execution of phase one to phase three programs. Lida has successfully delivered clearance of several Investigational New Drug applications for first-in-human CAR-T cell programs and has extensive experience with health authority interactions for marketing authorization submissions and approvals. Prior to joining Ichnos, Lida served as Vice President, Head of Clinical Development and Medical Affairs at Legend Biotech where she led the Janssen J&J partnership for global development of CARVYKTI (BCMA CAR-T) and established the company’s clinical capabilities for early portfolio pipelines (except China territory). She also previously worked on development of KYMRIAH (CD19 CAR-T) and AFINITOR (mTOR kinase inhibitor) at Novartis and AVASTIN (VEGF inhibitor mAb) at Hoffman la Roche. Lida received her medical degree and a certification in pediatrics from Tbilisi State Medical University in Georgia and served as a clinical research physician and investigator at Robert-Debré Hospital in Paris.

President and Head - Global Pharmaceutical Development

Ulhas Dhuppad

Ulhas is President and Head of Global Pharmaceutical Development at Glenmark Pharmaceuticals Limited, where he oversees generics research, specialty formulations, global regulatory affairs, project management and Bio equivalence Centre.

With over thirty-four years of experience, Ulhas has developed more than 300 products, including complex generics for the USA and Europe and specialty products for global markets. He has played a key role in designing development strategies, successfully filing niche products, and developing complex dosage forms. His expertise includes establishing systems for robust and timely product development.

He has held significant roles at Cadila Laboratories, Cipla, Lupin, Morepen and Alkem Laboratories. Ulhas has been working with Glenmark for 18 years, leading CMC development and contributing to building the Global Formulations R&D function. Ulhas holds a Master’s Degree in Pharmacy from Pune University.

EVP and Global Head - Innovative Business

Marco Cerato

Marco Cerato is Executive Vice President and Global Head – Innovative Business. He brings close to two decades of experience in the biotech and pharmaceutical industry, starting as a researcher and advancing to his current profile. Marco has had vast experience in managing global teams in Corporate and Business Development as well as Alliance and Portfolio Management across complex organizations. Marco has been passionate about building differentiated portfolios and finding avenues to deliver innovation for patients.

Prior to joining Glenmark, he was part of the executive team of Mundipharma as the Senior Vice President and Global Head of Corporate, Business Development and Alliance Management, before that he has held roles of increasing responsibility in leading organizations like Helsinn Healthcare, Aptalis Pharma and Eurand S.p.A.

Marco holds a Master’s Degree in Industrial Biotechnologies from Milano Bicocca University and a Master’s in Business Administration from SDA Bocconi.

President and Global Head – Formulation Operations

Brijlal Motwani

Brijlal is President and Global Head – Formulation Operations at Glenmark, where he oversees demand and supply planning, procurement, project management and strategic change management initiatives, at eleven state-of-the-art manufacturing facilities across India, the USA, Argentina and the Czech Republic.

With over three decades of experience in Manufacturing and Operations, Brij has led operations transformation programs for leading pharmaceutical organizations, both in India and internationally. He has been instrumental in enhancing productivity, debottlenecking operations, and developing long-term supply chain strategies. He has successfully guided multiple organisations through regulatory audits such as the U.S. FDA, MHRA, and ANVISA.

Before joining Glenmark in 2019, he was the Manufacturing Cluster Head at Zydus Lifesciences, overseeing several sites in India, the USA and Brazil. He also served as Regional Manufacturing Head at Sun Pharma, managing manufacturing sites in Africa, and has held positions with Ranbaxy Laboratories, Dr. Reddy’s Laboratories, Cipla and Macleods Pharmaceuticals across various locations in India and abroad.

Brij holds a postgraduate degree in Pharmacy from Nagpur University.

President and Chief Quality Officer

Indrajit Bose

Indrajit is President and Chief Quality Officer at Glenmark. He heads the Quality function for Glenmark’s eleven state-of-the-art manufacturing facilities across India, the USA, Argentina and the Czech Republic.

He brings with him over thirty years of rich and varied experience in the pharmaceutical industry, across quality and manufacturing of formulations and active pharmaceutical ingredients (API). He has successfully guided various organizations through regulatory audits like the U.S. FDA, MHRA, and ANVISA.

Before joining Glenmark in 2022, Indrajit headed global quality and compliance for Dr. Reddy’s Laboratories. He has also held senior leadership roles across leading pharmaceutical companies like Lupin, Alembic, Medley, IPCA and ORGANON.

He is a Pharmacy graduate from Birla Institute of Management, Mesra, Ranchi and completed his P.G.D.M. from Brilliant School of Management, Chennai.

EVP and Head – Legal, Compliance and Intellectual Property

Samir Kazi

Samir is Executive Vice President, and Head of Legal, Compliance and Intellectual Property at Glenmark Pharmaceuticals Limited. He is responsible for upholding high standards of ethics and business conduct within our organization.

Samir has over twenty-four years of global experience in corporate consulting, compliance, litigation, legal affairs, risk management, and M&A across various industries.

He has worked with Pfizer India, the Hinduja Group, Mulla & Mulla, and Craigie Blunt & Caroe.

Samir holds a Bachelor’s degree in Legislative Law from Mumbai University, as well as a BCom in Financial Accountancy and Taxation.

President and Chief Human Resources Officer

Alind Sharma

Alind is President and Chief Human Resources Officer at Glenmark Pharmaceuticals Limited. He drives organizational advancement through human capital strategy, in this capacity. His areas of focus include talent development, leadership development, and talent engagement.

Alind re-joined Glenmark, having previously worked with the company from 2002 to 2010. Before taking up his current role, he was the Vice President of Human Capital at Optum, part of United Health Group. He has also held senior positions at Pfizer, Monsanto, Tata International and Ranbaxy.

He is a Post-Graduate from Indian Institute of Management, Ahmedabad, India.

EVP - Information Technology

Edsel Pereira

Edsel is Executive Vice President – Information Technology. He oversees the Global IT function and serves as a crucial interface between business and IT.

With over 28 years of experience, he has been with Glenmark since 2012. Edsel also worked with Glenmark previously, from 1990 to 2005. Before rejoining Glenmark in 2012, he was Corporate Director IT at Hikma Pharmaceuticals PLC, UK.

He holds a Master of Management Studies in Finance from the University of Pune, a Diploma in Marketing Management, and is a Certified Information Systems Auditor (CISA).

Chief Communications & CSR

Shweta Munjal

shweta_bn02

Shweta Munjal is the Chief Communications & CSR Officer at Glenmark, bringing over 21 years of diverse, global experience across a spectrum of industries including Pharmaceuticals, Financial Services, FMCG, Retail and Technology. An internationally certified Mediator and a seasoned Values and Culture coach, Shweta’s career is marked by her profound expertise in Corporate Marketing, Corporate Communications, Branding, Digital Media, ESG and CSR.

Prior to joining Glenmark, Shweta excelled in leading Brand, Communications & Sustainability initiatives at Lupin. Her career includes pivotal roles at Nayara Energy, Thomson Reuters, Mondelez International, Intuit India, Tesco, Yahoo and NASSCOM, where she consistently demonstrated her strategic acumen and leadership in driving impactful marketing and communication strategies and sustainability initiatives.

Shweta holds a bachelor’s degree in Economics and masters in Mass Communication from the University of Delhi.

ABOUT US

INNOVATION

PRODUCTS

RESPONSIBILITY

INVESTORS

INVESTORS

CAREERS

MEDIA

Executive Team

© 2025 GLENMARK PHARMACEUTICALS LTD. ALL RIGHTS RESERVED